Endospan · raw details

Endospan developed low-profile stent graft systems for treating aneurysms and dissections throughout the aorta, including infrarenal, visceral, and thoracic. Its NEXUS Aortic Arch Stent Graft System received FDA approval in April 2026, leading to its acquisition by Artivion, Inc. in May 2026 for a base price of $175 million, with potential for up to an additional $200 million contingent on commercial performance. The company's innovative platform aimed to make the treatment of aortic lesions simpler and less invasive, offering solutions for patients with limited treatment options. Endospan was headquartered in Herzliya, Israel.